Search

Your search keyword '"Sookyoung Bae"' showing total 5 results
Start Over Author "Sookyoung Bae"
5 results on '"Sookyoung Bae"'

1. Table S4 from IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer

Author

A. Karolina Palucka, Joyce O'Shaughnessy, Virginia Pascual, Jacques Banchereau, George J. Snipes, Kyp L. Oxley, Alma-Martina Cepika, Jennifer L. Smith, Cheng-Han Chung, Sookyoung Bae, Maren K. Levin, Elizabeth Lavecchio, Gerlinde Obermoser, Florentina Marches, Hannah M. Brookes, Derek Blankenship, Xuan Wang, Sandra Zurawski, Kyung In Kim, Jacob Turner, Joshy George, Romain Banchereau, Robyn R. Young, Jan Martinek, Kangling Xu, and Te-Chia Wu

Abstract

Key resource table

Published
2023
Full Text
View/download PDF

2. Data from IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer

Author

A. Karolina Palucka, Joyce O'Shaughnessy, Virginia Pascual, Jacques Banchereau, George J. Snipes, Kyp L. Oxley, Alma-Martina Cepika, Jennifer L. Smith, Cheng-Han Chung, Sookyoung Bae, Maren K. Levin, Elizabeth Lavecchio, Gerlinde Obermoser, Florentina Marches, Hannah M. Brookes, Derek Blankenship, Xuan Wang, Sandra Zurawski, Kyung In Kim, Jacob Turner, Joshy George, Romain Banchereau, Robyn R. Young, Jan Martinek, Kangling Xu, and Te-Chia Wu

Abstract

Inflammation affects tumor immune surveillance and resistance to therapy. Here, we show that production of IL1β in primary breast cancer tumors is linked with advanced disease and originates from tumor-infiltrating CD11c+ myeloid cells. IL1β production is triggered by cancer cell membrane–derived TGFβ. Neutralizing TGFβ or IL1 receptor prevents breast cancer progression in humanized mouse model. Patients with metastatic HER2− breast cancer display a transcriptional signature of inflammation in the blood leukocytes, which is attenuated after IL1 blockade. When present in primary breast cancer tumors, this signature discriminates patients with poor clinical outcomes in two independent public datasets (TCGA and METABRIC).Significance: IL1β orchestrates tumor-promoting inflammation in breast cancer and can be targeted in patients using an IL1 receptor antagonist. Cancer Res; 78(18); 5243–58. ©2018 AACR.See related commentary by Dinarello, p. 5200

Published
2023
Full Text
View/download PDF

3. Supplementary figures from IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer

Author

A. Karolina Palucka, Joyce O'Shaughnessy, Virginia Pascual, Jacques Banchereau, George J. Snipes, Kyp L. Oxley, Alma-Martina Cepika, Jennifer L. Smith, Cheng-Han Chung, Sookyoung Bae, Maren K. Levin, Elizabeth Lavecchio, Gerlinde Obermoser, Florentina Marches, Hannah M. Brookes, Derek Blankenship, Xuan Wang, Sandra Zurawski, Kyung In Kim, Jacob Turner, Joshy George, Romain Banchereau, Robyn R. Young, Jan Martinek, Kangling Xu, and Te-Chia Wu

Abstract

Figure S1. Cytokines screening from breast tumor tissue Figure S2. IL-1β induces TSLP production from breast cancer cells. Figure S3. IL-1β production in DCs is caspase-1 dependent. Figure S4. IL-1β production requires TAK1-dependent caspase-1 activation. Figure S5. IL-1 and TGF-β mediate tumor-promoting type 2 cytokines in humanized mouse model. Figure S6. Cells component in blood from patients in clinical trial. Anakinra signature clustered breast cancer patients in TCGA dataset.

Published
2023
Full Text
View/download PDF

4. Guidelines for Mobile Laboratories for Molecular Diagnostic Testing of COVID-19.

Author

Kyoung Ho Roh, Ki Ho Hong, Myung-Hyun Nam, Taek Soo Kim, Moon-Woo Seong, Jin Kyung Lee, Sookyoung Bae, Hee Jae Huh, Jeong-Yeal Ahn, Jinsook Lim, Gab Jung Kim, Jae Sun Park, Hyun Yeong Kim, Cheon Kwon Yoo, and Hyukmin Lee

Subjects
COVID-19 testing, CLINICAL pathology, QUALITY control, LABORATORY safety, COVID-19, DIAGNOSTIC use of polymerase chain reaction, LABORATORY management
Abstract

With the rapid spread of the coronavirus disease (COVID-19), the need for rapid testing and diagnosis and consequently, the demand for mobile laboratories have increased. Despite this need, there are no clear guidelines for the operation, maintenance, or quality control of mobile laboratories. We provide guidelines for the operation, management, and quality control of mobile laboratories, and specifically for the implementation and execution of COVID-19 molecular diagnostic testing. These practical guidelines are primarily based on expert opinions and a laboratory accreditation inspection checklist. The scope of these guidelines includes the facility, preoperative evaluation, PCR testing, internal and external quality control, sample handling, reporting, laboratory personnel, biosafety level, and laboratory safety management. These guidelines are useful for the maintenance and operation of mobile laboratories not only in normal circumstances but also during public health crises and emergencies. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

5. IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer

Author

Hannah M. Brookes, A. Karolina Palucka, Sookyoung Bae, Kyp L. Oxley, Kyung In Kim, Kangling Xu, Elizabeth M. Lavecchio, Maren K. Levin, Romain Banchereau, George Snipes, Joshy George, Jan Martinek, Florentina Marches, Alma-Martina Cepika, Jennifer L. Smith, Sandra Zurawski, Virginia Pascual, Gerlinde Obermoser, Jacques Banchereau, Cheng-han Chung, Jacob Turner, Te-Chia Wu, Xuan Wang, Joyce O'Shaughnessy, Robyn R. Young, and Derek Blankenship

Subjects
0301 basic medicine, Cancer Research, medicine.drug_class, business.industry, Inflammation, medicine.disease, Receptor antagonist, Metastatic breast cancer, Blockade, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Breast cancer, Oncology, 030220 oncology & carcinogenesis, Humanized mouse, Cancer cell, Cancer research, medicine, medicine.symptom, Receptor, business
Abstract

Inflammation affects tumor immune surveillance and resistance to therapy. Here, we show that production of IL1β in primary breast cancer tumors is linked with advanced disease and originates from tumor-infiltrating CD11c+ myeloid cells. IL1β production is triggered by cancer cell membrane–derived TGFβ. Neutralizing TGFβ or IL1 receptor prevents breast cancer progression in humanized mouse model. Patients with metastatic HER2− breast cancer display a transcriptional signature of inflammation in the blood leukocytes, which is attenuated after IL1 blockade. When present in primary breast cancer tumors, this signature discriminates patients with poor clinical outcomes in two independent public datasets (TCGA and METABRIC). Significance: IL1β orchestrates tumor-promoting inflammation in breast cancer and can be targeted in patients using an IL1 receptor antagonist. Cancer Res; 78(18); 5243–58. ©2018 AACR. See related commentary by Dinarello, p. 5200

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results